Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 5
Anthracycline extravasation injuries: management with dexrazoxane
Authors Jordan K, Behlendorf T, Mueller F, Schmoll H
Published 8 May 2009 Volume 2009:5 Pages 361—366
DOI https://doi.org/10.2147/TCRM.S3694
Review by Single anonymous peer review
Peer reviewer comments 4
Karin Jordan, Timo Behlendorf, Franziska Mueller, Hans-Joachim Schmoll
Clinic for Internal Medicine IV, Department for Oncology and Haematology, University Hospital Halle, Halle, Germany
Abstract: The application of anthracyclines in anticancer therapy may result in accidental extravasation injury and can be a serious complication of their use. Tissue necrosis with skin ulceration is a possible outcome in the inadvertent extravasation of anthracyclines during intravenous administration. Until recently, there has been no effective treatment against the devastating effect of extravasated anthracycline. Preclinical and clinical studies are leading to the clinical implementation of dexrazoxane as the first and only proven antidote in anthracycline extravasation. In two multicenter studies dexrazoxane has proven to be highly effective in preventing skin necrosis and ulceration. This review focuses on the development and management of dexrazoxane in anthracycline extravasation injuries.
Keywords: dexrazoxane, extravasation, necrosis, anthracyclines
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.